GSK study includes Antigenics technology

06/5/2007 | Boston Globe (tiered subscription model), The

Biotech firm Antigenics said its Stimulon adjuvant technology is being used in a Phase III study by GlaxoSmithKline for its MAGE-A3 product to treat lung cancer. The firm's QS-21, which stimulates antibody responses, has been licensed by GSK and others for use in vaccines.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA